Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Bristol-Myers Squibb, Gilead to Sell Atripla in Canada

October 2, 2006

Expanding on their US joint venture launched in December 2004, drug makers Bristol-Myers Squibb Co. and Gilead Sciences have agreed to market their once-daily HIV treatment Atripla in Canada, pending approval by Health Canada. The companies will jointly file paperwork with Canadian regulators, and they will contribute funding and staff for the additional sales. Atripla -- which combines fixed doses of BMS' Sustiva and Gilead's Viread and Emtriva -- received US Food and Drug Administration approval in July.

Back to other news for October 2, 2006

Adapted from:
Associated Press
09.29.2006


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement